Luminex Corporation was incorporated in May 1995 and began commercial production of the first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. The Company’s open-architecture xMAP® Technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.
Luminex Vision Statement: Breakthrough solutions to improve health and advance science.
Closing share price
|FY, 2010||FY, 2011||FY, 2012||FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$10.7 m||$227 m||$237.7 m||$270.6 m|
Revenue growth, %
|$143.6 m||$159.9 m||$168.7 m|
Operating expense total
|$138.9 m||$131.7 m||$131.4 m|
|$4.8 m||$28.1 m||$37.4 m|
Income tax expense
|$6.1 m||$9.5 m||$10.4 m|
|$7.1 m||$39 m||$36.9 m||$13.8 m|
Operating cash flow
|$25.1 m||$23.8 m||$36.9 m|